Perceptis Medical

Coming – November 12

A Transformative Opportunity In Pediatric Care

Date and Time

November 12

–

12:00 PM ET / 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

Each year, more than 20 million pediatric ear infections are diagnosed in the U.S, and 1 million ear tube procedures are performed annually. Unfortunately, most of those procedures are performed in an operating room or surgical center, requiring general anesthesia and causing stress on parents and children.

Preceptis Medical is revolutionizing pediatric ear surgery through its FDA-cleared Hummingbird Tympanostomy Tube System (TTS). This breakthrough enables ear tube placement for children at a doctor’s office in just minutes (here’s a short video explaining the procedure), dramatically reducing healthcare costs. Hummingbird has already been used in over 6,000 procedures with a 99% success rate thanks to early adoption from ENTs, strong pull from pediatricians, and glowing reviews from parents.

Preceptis is poised for success thanks to:
  • Proven Market Traction: 40+ active accounts and $1M in annual revenue achieved with just one sales representative demonstrate validated demand and scalability.
  • High-Margin, High-Growth Model: 80%+ gross margins, CMS reimbursement coverage, and a total addressable market exceeding $2B globally.
  • Compelling Clinical and Societal Impact: By moving the procedure out of the OR and removing anesthesia risk, Preceptis is improving safety, reducing costs by up to 65%, and improving access to care.

Preceptis is led by a team with significant commercial experience with leading life science leaders including Stryker, Medtronic, Abbot, and others.

Join our online event with Preceptis CEO, Dave Carey, to hear about the company’s plans to expand its sales force and digital market leadership to meet surging demand from ENTs, pediatricians, and parents.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.